FY2025 net loss was $11.2M versus $24.5M in FY2024; no 2025 impairment (2024 included a $9.7M intangible impairment). Revenue was $0.3M in 2025 (DRP/service work); 2024 revenue was $0.0M. R&D expense was $6.6M (2024: $6.1M); G&A was $6.3M (2024: $11.4M), reflecting material cost control. Cash was $14.7M at 12/31/2025; management states cash funds operations at least into Q2 2027. Share repurchases totaled $3.19M (2,949,639 shares) under a $5M buyback authorized March 3, 2025; a new $5M 12‑month plan was approved Feb 2026. ATM equity raised net $9.7M in 2025; PIPE/pre-funded warrants added net $2.7M in late 2025; ATM facility is fully utilized and terminated. SEC investigation settled March 13, 2025 with a $2.5M civil penalty paid April 2025; a related class action was dismissed Feb 26, 2025. Novartis terminated the dovitinib license (Jan 26, 2024); $5.5M became immediately due including interest (recorded as current liabilities split across A/P, accrued interest, and a $1.4M note). Stenoparib is the sole focus: Phase 2 in platinum-resistant/ineligible ovarian cancer initiated June 2025 (40 patients; DRP-guided); Fast Track granted in Q3 2025; a VA-funded SCLC combo trial opened Jan 2026. Shares outstanding were 15,818,980 as of March 30, 2026; authorized common shares were reduced to 250,000,000 on Sept 9, 2024.